ACADIA PHARMACEUTICALS INC. Income (Loss) from Equity Method Investments
ACADIA PHARMACEUTICALS INC. (ACAD) reported Income (Loss) from Equity Method Investments of $138.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. income (loss) from equity method investments for fiscal 2025 was $138.90M, a 46.18% decline from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. income (loss) from equity method investments for fiscal 2024 was $258.07M.
- ACADIA PHARMACEUTICALS INC. income (loss) from equity method investments for fiscal 2023 was -$51.04M.
- ACADIA PHARMACEUTICALS INC. income (loss) from equity method investments for fiscal 2022 was -$213.44M.
| Period end | Income (Loss) from Equity Method Investments 12 month |
|---|---|
| 2025-12-31 | $138.90M 10-K · filed 2026-02-26 |
| 2024-12-31 | $258.07M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$51.04M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$213.44M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$167.52M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$280.97M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$234.38M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |